These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28093216)

  • 1. Longitudinal variation of serum periostin levels in adults with stable asthma.
    Semprini R; Caswell-Smith R; Fingleton J; Holweg C; Matthews J; Weatherall M; Beasley R; Braithwaite I;
    J Allergy Clin Immunol; 2017 May; 139(5):1687-1688.e9. PubMed ID: 28093216
    [No Abstract]   [Full Text] [Related]  

  • 2. Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma.
    Nagasaki T; Matsumoto H; Kanemitsu Y; Izuhara K; Tohda Y; Horiguchi T; Kita H; Tomii K; Fujimura M; Yokoyama A; Nakano Y; Hozawa S; Ito I; Oguma T; Izuhara Y; Tajiri T; Iwata T; Ono J; Ohta S; Yokoyama T; Niimi A; Mishima M
    Am J Respir Crit Care Med; 2014 Dec; 190(12):1449-52. PubMed ID: 25496105
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort.
    Sunadome H; Matsumoto H; Tohda Y; Horiguchi T; Kita H; Kuwabara K; Tomii K; Otsuka K; Fujimura M; Ohkura N; Iwanaga T; Hozawa S; Niimi A; Kanemitsu Y; Nagasaki T; Tashima N; Ishiyama Y; Morimoto C; Oguma T; Tajiri T; Ito I; Ono J; Ohta S; Izuhara K; Hirai T
    Allergol Int; 2021 Apr; 70(2):252-254. PubMed ID: 33218953
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids.
    Kanemitsu Y; Matsumoto H; Izuhara K; Tohda Y; Kita H; Horiguchi T; Kuwabara K; Tomii K; Otsuka K; Fujimura M; Ohkura N; Tomita K; Yokoyama A; Ohnishi H; Nakano Y; Oguma T; Hozawa S; Nagasaki T; Ito I; Oguma T; Inoue H; Tajiri T; Iwata T; Izuhara Y; Ono J; Ohta S; Tamari M; Hirota T; Yokoyama T; Niimi A; Mishima M
    J Allergy Clin Immunol; 2013 Aug; 132(2):305-12.e3. PubMed ID: 23791506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The other side of asthma: Steroid-refractory disease in the absence of TH2-mediated inflammation.
    Gelfand EW; Alam R
    J Allergy Clin Immunol; 2015 May; 135(5):1196-8. PubMed ID: 25772592
    [No Abstract]   [Full Text] [Related]  

  • 7. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation.
    Caminati M; Gatti D; Dama A; Lorenzetti L; Senna G
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):460-462. PubMed ID: 28941707
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent developments regarding periostin in bronchial asthma.
    Izuhara K; Matsumoto H; Ohta S; Ono J; Arima K; Ogawa M
    Allergol Int; 2015 Sep; 64 Suppl():S3-10. PubMed ID: 26344077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum periostin: a novel biomarker for asthma management.
    Matsumoto H
    Allergol Int; 2014 Jun; 63(2):153-60. PubMed ID: 24759559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics.
    Konstantellou E; Loukides S; Ntontsi P; Papathanasiou E; Kostikas K; Paptheodorou G; Hillas G; Papiris S; Koulouris NG; Bakakos P
    J Allergy Clin Immunol Pract; 2017; 5(4):1129-1131.e3. PubMed ID: 28396112
    [No Abstract]   [Full Text] [Related]  

  • 13. Sensitization at the first wheezing episode increases risk for long-term asthma therapy.
    Lukkarinen M; Vuorinen T; Lehtinen P; Ruuskanen O; Jartti T
    Pediatr Allergy Immunol; 2015 Nov; 26(7):687-91. PubMed ID: 26131610
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of early treatment on the progression of asthma.
    National Asthma Education and Prevention Program
    J Allergy Clin Immunol; 2002 Nov; 110(5 Suppl):S196-219. PubMed ID: 12518562
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing biomarkers in a real-world severe asthma study (ARIETTA).
    Buhl R; Korn S; Menzies-Gow A; Aubier M; Chapman KR; Canonica GW; Picado C; Martin N; Escobar RA; Korom S; Hanania NA
    Respir Med; 2016 Jun; 115():7-12. PubMed ID: 27215497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenge of diagnosing a mixed asthma-COPD phenotype (ACOS) in clinical practice.
    García-García Mdel C; Hernández-Borge J; Barrecheguren M; Miravitlles M
    Ther Adv Respir Dis; 2016 Apr; 10(2):175-8. PubMed ID: 26968234
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in the use of anti-asthmatic medication in an international cohort.
    Janson C; de Marco R; Accordini S; Almar E; Bugiani M; Carolei A; Cazzoletti L; Cerveri I; Corsico A; Duran-Tauleria E; Gislason D; Gulsvik A; Jõgi R; Marinoni A; Martínez-Moratalla J; Pin I; Vermeire P; Jarvis D
    Eur Respir J; 2005 Dec; 26(6):1047-55. PubMed ID: 16319334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of systemic corticosteroids on serum apoptotic markers and quality of life in patients with asthma.
    Bhargava S; Prakash A; Rehan HS; Gupta LK
    Allergy Asthma Proc; 2015; 36(4):275-82. PubMed ID: 26108085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers and asthma management: analysis and potential applications.
    Richards LB; Neerincx AH; van Bragt JJMH; Sterk PJ; Bel EHD; Maitland-van der Zee AH
    Curr Opin Allergy Clin Immunol; 2018 Apr; 18(2):96-108. PubMed ID: 29389730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.